Molecular Targets & Therapeutics

Microscopic view of glioblastoma tumor cells

Helmholtz Munich, together with the University of Münster and ITM Isotope Technologies Munich SE (ITM), has reported updated preliminary results from a Phase 1 clinical trial evaluating ITM-31, a targeted radiotherapy for glioblastoma. The treatment…

Prof. Marcus Conrad has been elected a member of the German National Academy of Sciences Leopoldina. With this prestigious scientific honor, the Academy recognizes his outstanding contributions to the study of regulated cell death and its…

11.6.2026

Pascal speaks at HAICON 2026 - The interaction layer: why the virtual cell needs biochemistry

A new study clarifies the role of the RNA methyltransferase METTL5, showing that it does not modify mRNA in living cells but is instead restricted to rRNA.

central cancer cell being attacked by surrounding immune cells (t-cells). Ideal for medical, scientific, oncology, and health-related content

Helmholtz Munich has licensed fusion receptor technologies to the Champalimaud Foundation, where they are being used together with newly acquired T cell receptor assets to support research into engineered T cell therapies.